Latest News and Press Releases

Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submissionRecruitment and screening update for Travelan® Controlled Human Infection Model (CHIM)...

Highlights: Immuron receives approval from U.S. Army Medical Research and Development CommandRecruitment and screening of healthy volunteers for Travelan® Controlled Human Infection Model (CHIM)...

Highlights: First participants enrolled in USU Travelan Clinical Trial Field Study157 participants successfully randomized into the Clinical StudyPlans in place to enrol in 1302 healthy volunteers in...

Highlights: Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA)Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the...

Highlights: Clinical Trial Master Service Agreement with US-based Pharmaron ExecutedInvestigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA)Plans in...

Key Points International Patent Filed Publication from the Hebrew University - Hadassah Medical Center Entitled: Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical...

Key Points Monash University Research Update on SARS-CoV-2 programBiomedicine Discovery Institute initiates program to isolate and identify the inhibitory molecule/s in IMM-124E Appointment of Chief...

Key Points Immuron’s IMM-124E IND Program recommencesUniformed Services University to recommence planned Travelers’ Diarrhea clinical studyCOVID-19 - Consultancy Agreement with Infectious Disease...

Key Highlights: Travelan® shigellosis challenge studies in non-human primates successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals...

Key Highlights: Immuron achieved 66% YoY growth in worldwide sales for the third quarter of FY19, ending March 31, 2019.In Australia Q3 sales of Travelan® surged ahead, growing 73% YoY.In the US Q3...